Clorox (CLX) Q1 2026 earnings review
ERP Transition Noise Obscures Underlying Trends; FY26 Guidance Maintained Despite Q1 Collapse
Clorox reported a sharp, but largely anticipated, decline in Q1 results, with organic sales falling 17% and Adjusted EPS down 54%. The declines were driven by the reversal of a significant inventory build by retailers in the prior quarter ahead of the company's new ERP system launch. Management maintained its full-year guidance but now expects results toward the lower end of the range, citing temporary market share losses and fulfillment issues from a rockier-than-expected ERP transition. The core narrative is a 'tale of two halves,' with the business expected to return to underlying growth in the second half of the fiscal year, driven by a new innovation pipeline.
🐂 Bull Case
The massive Q1 decline was a planned, mechanical reversal of Q4's inventory build. With the ERP system now live, this major source of volatility is in the rearview mirror, allowing focus to return to underlying business trends.
Despite the severe Q1 results and execution stumbles, management felt confident enough in the back-half recovery plan to maintain its full-year sales, margin, and EPS guidance, suggesting the issues are contained.
The company noted that its outlook for input cost inflation has improved slightly, providing a modest tailwind that can help fund investments needed to regain momentum in the second half.
🐻 Bear Case
The ERP transition was not seamless. Management admitted the ramp-up was slower than expected, leading to fulfillment disruptions that hurt market share. Recovering this share in a competitive market will require investment and time.
The company's planned back-half recovery relies on new innovation, but it faces a tough backdrop with underlying category growth estimated at a sluggish 0-1%. Gaining traction in a weak market is a significant challenge.
The forecast of shifting from negative underlying growth in H1 to positive growth in H2 creates a high-pressure execution scenario. Any delays in innovation or further consumer weakness could jeopardize the full-year targets.
⚖️ Verdict: 🔴
Bearish. While the mechanical nature of the ERP-related sales decline was expected, the self-inflicted wounds of market share loss and fulfillment disruptions are concerning. Maintaining guidance while flagging these issues and pointing to the lower end of the range suggests reduced confidence. The reliance on a second-half recovery in a weak consumer environment makes the risk profile unfavorable in the near term.
Key Themes
The ERP Hangover: A Planned but Painful Quarter
The quarter's results were dominated by the mechanical reversal of inventory shipments. In Q4 FY25, Clorox shipped about two weeks of extra inventory to retailers to de-risk its ERP go-live. In Q1, retailers sold through that excess stock, causing shipments to plummet. The company quantifies this year-over-year impact as a 14-point drag on sales growth and a $0.90 drag on adjusted EPS, explaining nearly the entire variance. While anticipated, the sheer magnitude of the disruption created extreme volatility in reported results.
Execution Stumble: 'Planned' Disruption Caused Unplanned Share Loss
A key concern is that the ERP transition was not as smooth as the 'planned' narrative suggests. Management admitted on the call that they "experienced some temporary disruptions that affected our market share" and that the fulfillment ramp-up was "a little slower than expected." This contradicts the idea of a perfectly managed event and reveals a tangible, negative business impact that now requires corrective action and investment to fix.
Innovation Pipeline is Key to Second-Half Recovery
Management's entire thesis for a second-half inflection rests on a robust innovation pipeline. New product launches mentioned include Clorox Screen+ Wipes, new Glad ForceFlex scents, Hidden Valley Ranch Dippers, and platform expansions for Burt’s Bees into body lotions. The company is backing these launches with advertising spend projected at ~11% of sales for the full year, viewing this as the primary lever to reinvigorate growth.
A Tale of Two Halves
The company's FY26 plan is starkly back-half weighted. Management guided that, excluding the ERP noise, underlying organic sales growth will be in the 'negative low single digits' for the first half of the year. This is expected to inflect to 'positive low single digits' in the second half, driven by innovation, lapping weak trends, and normalizing market conditions. This cadence sets a clear, but challenging, benchmark for the next few quarters.
Sluggish Consumer Demand and Competitive Pressures Persist
The macroeconomic backdrop remains a headwind. The company assumes its categories will only grow 0% to 1% in FY26, well below historical averages. Concurrently, the competitive environment remains intense, with management noting increased promotions in the Trash and Cat Litter businesses. This combination of a slow market and heightened competition makes it more difficult to achieve the planned second-half acceleration.
Other KPIs
Reversing. After 10 consecutive quarters of expansion, gross margin collapsed by 410 basis points from 45.8% a year ago. The drop was primarily driven by significant volume deleveraging from the lower shipments, as well as higher manufacturing and logistics costs. This marks a sharp reversal of a multi-year recovery trend.
The impact of lower shipments was felt across all segments, with Adjusted EBIT declining sharply: Health and Wellness (-47%), Household (-55%), Lifestyle (-42%), and International (-46%). This demonstrates the widespread operational deleverage and shows that no single segment was insulated from the ERP transition effects.
Down 58% from $221 million in the prior-year period. The significant decrease in cash flow is a direct result of the lower net earnings caused by the ERP-related shipment decline, highlighting the real cash impact of the transition.
Guidance
Decelerating. The midpoint of $6.125 represents a 21% decline from FY25's $7.72. However, the guidance includes an approximate $0.90 headwind from the ERP inventory reversal. Adjusting for this one-time impact, the 'underlying' EPS guidance would be closer to $7.03, implying a core business decline of about 9% YoY. The company expects to finish at the lower end of the guided range.
Reversing. This reverses the +5% growth in FY25. The guidance includes a negative 7.5 percentage point impact from the ERP shipment reversal. This implies an 'underlying' organic sales performance between -1.5% and +2.5% for the full year, which aligns with the company's narrative of a flat-to-slightly-improving core business.
Reversing. This outlook implies a full-year margin between 44.2% and 44.7% (vs 45.2% in FY25). The guidance includes a 100 bps headwind from the ERP reversal, suggesting that the underlying 'core' gross margin is expected to be roughly flat to up 50 bps, supported by cost savings that offset inflation.